Jon Riley Hays v. United States

397 F.3d 564, 2005 U.S. App. LEXIS 2162, 2005 WL 310871
CourtCourt of Appeals for the Seventh Circuit
DecidedFebruary 10, 2005
Docket04-2456
StatusPublished
Cited by61 cases

This text of 397 F.3d 564 (Jon Riley Hays v. United States) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jon Riley Hays v. United States, 397 F.3d 564, 2005 U.S. App. LEXIS 2162, 2005 WL 310871 (7th Cir. 2005).

Opinion

KANNE, Circuit Judge.

Jon Riley Hays, a licensed medical doctor, pled guilty to two charges stemming from his illegal use of OxyContin. Count I charged Hays with tampering with a consumer product, and Count II charged him with possession of a controlled substance by misrepresentation or fraud. Hays was sentenced to fifty-one months in prison for Count I and a concurrent sentence of forty-eight months for Count II. Hays now asks for collateral relief under 28 U.S.C. § 2255, claiming that his attorneys provided ineffective assistance and that his plea was not voluntary because he did not understand the nature of the charges against him. The district court denied his motion. For the reasons set forth in this opinion, we affirm.

I. History

Hays practiced medicine in several towns in rural Illinois. In early 2000, he was involved in a car accident which caused injury to his back. He began taking OxyContin to relieve his pain and became addicted to the drug. Although the recommended oral dosage was 20 to 40 mg per day, Hays would often inject approximately 300 mg of the drug in a day.

In order to gain access to such a large amount of OxyContin, Hays prescribed it to his patients and then stole the drug from them during house calls. How he did this is in some dispute. The state argues that he crushed the OxyContin tablets, dissolved the particles in a syringe, and injected the patient with a portion of the dissolved drug. He then left with a syringe filled with the drug and some of the remaining tablets for his own use. Hays denies that he injected patients with the dissolved OxyContin, stating that he thought “crushing something ... would be dangerous.” He claims that he occasionally broke pills in half or prescribed more of the drug than the patient needed so that he could take some of the pills for himself. He also injected some patients with a placebo (i.e., Iidocaine or saline) so that he could inject the entire dosage of OxyCon-tin into himself.

Under Count I of the indictment, Hays was charged with tampering with a consumer product:

Whoever, with reckless disregard for the risk that another person will be placed in danger of death or bodily injury and under circumstances manifesting extreme indifference to such risk, tampers with any consumer product that affects interstate or foreign commerce ... [shall] be fined under this title or imprisoned not more than ten years, or both.

18 U.S.C. § 1365(a), (a)(4). Count II alleged that Hays had “acquire[d] or obtained] possession of a controlled substance by misrepresentation, fraud, forgery, deception, or subterfuge.” 21 U.S.C. § 843(a)(3). Hays pled guilty to these charges but now seeks relief from his fifty-one month sentence under 28 U.S.C. § 2255.

II. Analysis

Relief under § 2255 “is reserved for extraordinary situations.” Prewitt v. United States, 83 F.3d 812, 816 (7th Cir.1996) (citing Brecht v. Abrahamson, 507 U.S. 619, 633-34, 113 S.Ct. 1710, 123 L.Ed.2d 353 (1993)). The court may vacate or correct Hays’s sentence if he can “show that the district court sentenced him in violation of the Constitution or laws of the *567 United States or that the sentence was in excess of the maximum authorized by law or is otherwise subject to collateral attack.” Prewitt, 83 F.3d at 816 (citing Theodorou v. United States, 887 F.2d 1336, 1338 n. 2 (7th Cir.1989)). We review the district court’s denial of the § 2255 motion de novo. McCleese v. United States, 75 F.3d 1174, 1177 (7th Cir.1996).

In order for a plea to be valid, it must be made voluntarily, knowingly, and intelligently. See United States v. Gilliam, 255 F.3d 428, 432-33 (7th Cir.2001) (citing McCarthy v. United States, 394 U.S. 459, 466, 89 S.Ct. 1166, 22 L.Ed.2d 418 (1969)). Hays now argues that his plea was not intelligent or voluntary and that his attorney provided ineffective assistance.

A. Hays’s Conduct Affected Interstate Commerce

A guilty plea is not made intelligently unless the defendant receives “real notice of the true nature of the charge against him_” Smith v. O’Grady, 312 U.S. 329, 334, 61 S.Ct. 572, 85 L.Ed. 859 (1941). Hays argues that because “neither [Hays], nor his counsel, nor the court correctly understood the essential elements of the crime with which he was charged,” the guilty plea is not valid. See Bousley v. United States, 523 U.S. 614, 618-19, 118 S.Ct. 1604, 140 L.Ed.2d 828 (1998). The misunderstanding that Hays alleges relates to the interstate commerce element of 18 U.S.C. § 1365(a).

Hays relies on a Tenth Circuit decision as support for his argument that neither his counsel nor the court truly understood what was necessary for proving the interstate commerce element of § 1365(a). In United States v. Levine, the court held that “the effect on interstate commerce must occur at or after the tainting.” 41 F.3d 607, 614 (10th Cir.1994). The court noted that “the interstate commerce requirement is phrased in the present tense.” Id. Therefore, it should be read to penalize one who tampers with a product that “affects interstate commerce.” This “suggests that the consumer product must have either a present effect or an effect in the future, and appears to exclude pre-tainting events.” Id.

At the change of plea hearing, the court established that OxyContin is manufactured in Minnesota and that the tampering occurred in Illinois. This was taken as adequate evidence of an effect on interstate commerce. Hays believes that the question should have been whether the drug had any effect on interstate commerce after Hays gained access to the OxyContin at the homes of his patients. He argues that his lawyers should have been aware of Levine and should have advised him not to plead guilty.

Even if it is on point, a Tenth Circuit decision is not binding on courts in other circuits. See United States v. Glaser,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Blacharski v. United States
N.D. Indiana, 2025
Beachem v. United States
N.D. Indiana, 2025
Sanabria v. United States
N.D. Indiana, 2025
Lindsey v. United States
N.D. Indiana, 2025
Glass v. United States
N.D. Indiana, 2025
Briggs v. United States
N.D. Indiana, 2025
Decker v. United States
N.D. Indiana, 2025
Burns v. United States
N.D. Indiana, 2025
Hansford v. United States
N.D. Indiana, 2025
Johnson v. United States
N.D. Indiana, 2025
Walton v. United States
N.D. Indiana, 2024
Jordan v. United States
W.D. Wisconsin, 2024
Dawson v. United States
N.D. Indiana, 2024
Jackson v. United States
N.D. Indiana, 2024
Pedraza v. United States
N.D. Indiana, 2024
Griffis v. United States
N.D. Indiana, 2024
Bolden v. United States
N.D. Indiana, 2024

Cite This Page — Counsel Stack

Bluebook (online)
397 F.3d 564, 2005 U.S. App. LEXIS 2162, 2005 WL 310871, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jon-riley-hays-v-united-states-ca7-2005.